NeoImmuneTech, Inc. (KOSDAQ:950220)
South Korea · Delayed Price · Currency is KRW 2,590.00
+85.00 (3.39%)
Sep 1, 2026, 3:30 PM KST
NeoImmuneTech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,760 | 94.82 | 170.38 | - | - | - | |
Revenue Growth | 744.13% | -44.35% | - | - | - | - |
Gross Profit | 1,510 | 94.82 | 170.38 | - | - | - |
Selling, General & Admin | 23,861 | 22,817 | 36,534 | 52,369 | 55,326 | 50,090 |
Research & Development | -4,130 | - | - | - | - | - |
Amortization of Goodwill & Intangibles | 940.9 | 655.52 | 529.12 | 506.4 | 501.18 | 443.95 |
Operating Expenses | 22,626 | 25,434 | 41,143 | 55,847 | 58,182 | 51,906 |
Operating Income | -21,117 | -25,339 | -40,972 | -55,847 | -58,182 | -51,906 |
Interest Expense | -2,504 | -2,424 | -726.09 | -225.28 | -261.39 | -219.15 |
Interest & Investment Income | 1,301 | 1,255 | 1,788 | 2,877 | 1,154 | 390.88 |
Currency Exchange Gain (Loss) | -3,088 | -1,859 | -1,335 | -128.89 | -3,005 | -589.4 |
Other Non Operating Income (Expenses) | 942.44 | -3,614 | 1,187 | 23.06 | 18.52 | 15.46 |
EBT Excluding Unusual Items | -24,465 | -31,981 | -40,059 | -53,301 | -60,276 | -52,308 |
Gain (Loss) on Sale of Assets | 30.38 | 213.95 | -321.85 | -1.91 | -13.03 | -104.72 |
Asset Writedown | -0.02 | -40.1 | -488.92 | - | - | - |
Pretax Income | -24,435 | -31,807 | -40,870 | -53,303 | -60,289 | -52,413 |
Income Tax Expense | 12.83 | -11.37 | 12.83 | 101.3 | 116.41 | 69.47 |
Net Income | -24,448 | -31,796 | -40,883 | -53,405 | -60,406 | -52,482 |
Net Income to Common | -24,448 | -31,796 | -40,883 | -53,405 | -60,406 | -52,482 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 125 | 118 | 99 | 99 | 99 | 95 |
Shares Outstanding (Diluted) | 125 | 118 | 99 | 99 | 99 | 95 |
Shares Change | 110.94% | 19.34% | -0.24% | 0.08% | 3.68% | 15.27% |
EPS (Basic) | -196.21 | -270.20 | -414.60 | -540.26 | -611.60 | -550.94 |
EPS (Diluted) | -196.21 | -270.20 | -414.60 | -540.40 | -611.60 | -550.94 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -23,721 | -25,133 | -40,612 | -50,552 | -44,881 | -36,596 |
Free Cash Flow Per Share | -190.38 | -213.57 | -411.85 | -511.40 | -454.42 | -384.18 |
Gross Margin | 85.79% | 100.00% | 100.00% | - | - | - |
Operating Margin | -1199.82% | -26721.84% | -24047.07% | - | - | - |
Profit Margin | -1389.10% | -33531.39% | -23994.58% | - | - | - |
Free Cash Flow Margin | -1347.80% | -26504.37% | -23835.33% | - | - | - |
EBITDA | -18,291 | -22,841 | -37,299 | -52,637 | -55,380 | -50,033 |
D&A For EBITDA | 2,825 | 2,498 | 3,673 | 3,210 | 2,802 | 1,873 |
EBIT | -21,117 | -25,339 | -40,972 | -55,847 | -58,182 | -51,906 |